• Latest Posts

12 European Biotechs which ‘stole the show’ at World most Important Cancer Meeting

UK Drug Discovery sells Cancer Target to German Pharma

A Relief for Migraines at last? The Biotech race for the Ultimate Cure

Boehringer Ingelheim Gets €540M upfront for the next Potential Antibody Blockbuster

Novartis Attacks Amgen. Amgen wants to Ruin Roche – The New Biosimilar War!

Ablynx richly rewarded for MSD’s Nanobody Proof in Immuno-Oncology


Asceneuron’s latest stab at the Alzheimer’s challenge with Sofinnova

Crowdsourcing for Innovation: BioMed X has just the right Recipe

Researcher in Cardiovascular disease? Apply to this new €1,6M Competition for the next treatment

Boehringer Ingelheim signs €661M deal for New Lung Cancer Treatment

Ablynx and MSD upgrade their €1.7Bn deal to gigantic €5.7Bn

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition